Haochun Jin; Dianxin Cui; Yu Fan; Guodong Li; Zhangfeng Zhong; Yitao Wang
Drug Discov. Today, 2024, 103885
https://doi.org/10.1016/j.drudis.2024.103885

Abstract

Bioaffinity drug screening strategies have gained popularity in preclinical and clinical drug discovery for natural products, small molecules and antibodies owing to their superior selectivity, the large number of compounds to be screened and their ability to reduce the time and cost of the drug discovery process. This paper provides a systematic summary of the principles of commonly used bioaffinity-based screening methods, elaborates on the success of bioaffinity in clinical drug development and summarizes the active compounds, preclinical drugs and marketed drugs obtained through affinity screening methods. Owing to the high demand for new drugs, bioaffinity-guided screening techniques will play a greater part in clinical drug development. Teaser: Here, we analyze the different affinity screening methods and their clinical outcomes, underscoring the significance of this technique in drug discovery.